- Home
- TSHA vs PLGO Comparison
TSHA vs PLGO Comparison
Compare TSHA & PLGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TSHA | PLGO |
|---|---|---|
| Founded | 2019 | N/A |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | TSHA | PLGO |
|---|---|---|
| Price | $6.65 | $24.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $11.63 | N/A |
| AVG Volume (30 Days) | ★ 3.6M | 487.0K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,773,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,152.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.28 | N/A |
| 52 Week Low | $2.33 | $22.80 |
| 52 Week High | $7.30 | $24.95 |
Technical Indicators
Market Signals| Indicator | TSHA | PLGO |
|---|---|---|
| Relative Strength Index (RSI) | 58.83 | 82.45 |
| Support Level | $4.24 | N/A |
| Resistance Level | $6.76 | N/A |
| Average True Range (ATR) | 0.43 | 0.65 |
| MACD | 0.07 | 0.20 |
| Stochastic Oscillator | 75.27 | 96.24 |
Price Performance
Historical ComparisonAbout TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.